Miach Orthopaedics, a Westborough, MA-based company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration (BEAR®) Implant, raised $20M in Series B funding.
Backers included Major League Soccer Players Association (MLSPA), SV Health Investors and Aperture Venture Partners and existing investors Amzak Health, Smith+Nephew, DSM Venturing, Sectoral Asset Management, Endeavour Vision and the NFL Players Association (NFLPA). SV Health Investors will be represented on the Miach board of directors.
Led by Patrick McBrayer, President and CEO, Miach Orthopaedics is dedicated to developing bio-engineered surgical implants for connective tissue restoration. The company’s initial focus is the BEAR® Implant, which has been used to treat nearly 3,000 patients with anterior cruciate ligament (ACL) tears.
Unlike reconstruction, which is the current standard of care, the BEAR Implant does not require a second surgical wound site to remove a healthy tendon from another part of the leg or the use of a donor tendon. The implant acts as a bridge to help ends of the torn ACL heal together. The surgeon injects a small amount of the patient’s own blood into the implant and attaches it between the torn ends of the ACL in a minimally invasive procedure. The combination of the implant and the patient’s blood enables the body to heal the torn ends of the ACL back together while maintaining the ACL’s original attachments to the femur and tibia. As the ACL heals, the implant is resorbed by the body.
The BEAR Implant was granted De Novo Approval from the U.S. Food and Drug Administration in December 2020. It is indicated for skeletally mature patients at least 14 years of age with a complete rupture of the ACL as confirmed by MRI. Patients must have an ACL stump attached to the tibia to facilitate the restoration. Visit miachortho.com for complete product information, including Instructions for Use.
The company intends to use the funds to support commercial expansion and clinical activities for the BEAR Implant.
FinSMEs
03/04/2024